Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/26/15 | Notice of Effectiveness |
|
1 | ||
| 10/22/15 | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | ||
| 10/20/15 | Confidential treatment order |
|
1 | ||
| 10/08/15 | SEC-generated letter |
|
2 | ||
| 10/06/15 | Current report filing |
|
3 | ||
| 09/28/15 | Registration statement for specified transactions by certain issuers |
|
187 | ||
| 09/21/15 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 08/21/15 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 08/20/15 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 08/20/15 | Statement of changes in beneficial ownership of securities |
|
1 |